Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine. The company also offers Xenon, a radiopharmaceutical gas used to assess pulmonary function, and to image cerebral blood flow; Neurolite, an injectable to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable technetium-labeled imaging agent; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium TI 201 for use in MPI studies to detect cardiovascular disease; Gallium Ga 67 to detect various infections and cancerous tumors; and Quadramet, a therapeutic product. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; and LMI 1195 that is in Phase III clinical trials for the diagnosis and treatment of neuroendocrine tumors. It serves radiopharmacies, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic collaborations with NanoMab Technology Limited to provide an imaging biomarker research tool to pharmaceutical companies and academic centers conducting R&D on PD-L1 immuno-oncology treatments; Insightec Ltd. for the treatment of glioblastoma and neurodegenerative conditions; and POINT Biopharma, Inc. to treat metastatic castration resistant prostate cancer. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
|Price/Operating Income||very cheap|
|Debt Ratio||very low|
|Dividend Yield||very low|
|Sales growth (1y)||average|
|Sales growth (3y)||average|
|Earnings growth (1y)||very low|
|Earnings growth (3y)||very low|